Highlights
- Participants reported better sleep quality, with statistically significant reductions in sleep disturbance and sleep problem indices by both day 15 and day 30.
- Stress, anxiety, and depressive symptoms declined, while fatigue — especially physical fatigue — improved steadily throughout the study.
- PROMIS-29 results showed gains in physical function, emotional well-being, and pain reduction, along with a significant improvement in sleep disturbance.
- Physiological trends suggested improved autonomic balance, brain oxygenation, and mitochondrial activity, supporting greater systemic resilience.
- Findings indicate NanoVi Exo® may help enhance sleep, mood, and energy balance naturally and non-invasively, warranting further research in larger, controlled trials.
Introduction
Aging is often accompanied by physiological decline, greater vulnerability to stress and fatigue, and challenges with sleep quality. Interventions that can support both cellular and systemic resilience are of growing interest in promoting well-being among older adults. This exploratory study set out to investigate the wellness effects of daily NanoVi Exo® sessions on sleep, mood, fatigue, and physiological health markers in individuals aged 60 and older.
Intervention
Nine adults (mean age 70 years) participated in a 30-day program involving daily 20-minute NanoVi Exo® sessions. At baseline, day 15, and day 30, participants completed validated questionnaires including the MOS Sleep Scale, DASS-21, Chalder Fatigue Scale (CFS), and PROMIS-29. Physiological measures — photoplethysmography (PPG) Stress Flow, hemoencephalography (HEG), and mitochondrial biomarker analysis (mescreen™) — were taken at baseline and post-intervention.
Results
Participants reported notable improvements in self-perceived sleep quality, with statistically significant reductions in sleep disturbance (p = 0.0367) and sleep problem indices at both 15 days (p = 0.0214) and 30 days (p = 0.0143). Large effect sizes were seen in sleep adequacy, reduced somnolence, and overall sleep quality. Stress, anxiety, and depressive symptoms also decreased, alongside consistent improvements in fatigue — particularly in the physical fatigue domain. PROMIS-29 data indicated trends toward better physical function, less pain interference, and enhanced emotional well-being, with a statistically significant improvement in sleep disturbance (p = 0.0228).
Physiological data showed favorable, though not statistically significant, trends in heart rate variability, cerebral oxygenation, and autonomic balance, with several measures approaching normative ranges. Mitochondrial biomarker analysis revealed increased baseline respiration (+8%), mitochondrial potential (+5%), and network connectivity (+19% baseline; +17% stressed). Aerobic metabolism improved (+7%), although results also indicated a higher glycolytic shift (+12%) and reduced mitochondrial efficiency (–6%), suggesting a possible compensatory adaptation.
Conclusions
Thirty consecutive days of daily NanoVi Exo® sessions were associated with improvements in perceived sleep quality, emotional well-being, fatigue, and pain among older adults, with supportive trends in physiological resilience. Mitochondrial biomarker data suggested increased respiratory activity and network connectivity but also pointed to a shift toward glycolytic metabolism and reduced efficiency, potentially reflecting early-stage or adaptive responses. These findings support further investigation in larger, controlled studies to clarify the long-term implications
This study was conducted using the NanoVi Exo® device, manufactured by Eng3 Corporation
Contact info: +1 206 525-0227
Eastlake Ave E Seattle, WA 98102
info@eng3.com
Figure 1. Improvements in Mean Heart rate, SDNN, RMSSD and Total Power parameters after 30 days of daily NanoVi Exo® sessions.
Figure 2. Enhanced parasympathetic activation and reduced sympathetic dominance after 30 days of daily NanoVi Exo® sessions.
Figure 3. Increased Cerebral Blood Oxygenation and cerebral blood flow parameters after 30 days of daily NanoVi Exo® sessions.
Figure 4. Improvements in multiple MOS Sleep scale components at midpoint and after 30 days of daily NanoVi Exo® sessions.
Figure 5. Reductions in Depression, Anxiety and Stress at midpoint and after 30 days of daily NanoVi Exo® sessions.
Figure 6. Reductions in Fatigue Severity Scale scores at midpoint and after 30 days of daily NanoVi Exo® sessions.
Figure 7. Increases in Mitochondrial Network Resilience after 30 Days of Daily NanoVi Exo® Sessions.
Link to full paper: Read here